| Trial | Add-Aspirin Trial |
|---|---|
| Cancer Type | Gastrointestinal, Genitourinary, Miscellaneous, Oesophageal Cancer, Prostate Cancer, Stomach Cancer, and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | A Phase III, Double-Blind, Placebo-Controlled Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival after Primary Therapy in Common Non-Metastatic Solid Tumours |
 |
Click Here to view CancerHelpUK trial summary |
| Trial | ICHOR |
|---|---|
| Cancer Type | Gastrointestinal, Oesophageal Cancer, and Stomach Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | Investigation of Circulating Haematological Biomarkers in Cancer |
| Trial | PLATFORM |
|---|---|
| Cancer Type | Gastrointestinal, Oesophageal Cancer, and Stomach Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | PLAnning Treatment For Oesophago-Gastric Cancer: a Randomised Maintenance Therapy Trial |
| Trial | PORCUPINE 2 STUDY |
|---|---|
| Cancer Type | Gastrointestinal, Miscellaneous, and Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care |
| Trial | Precision-Panc |
|---|---|
| Cancer Type | Gastrointestinal and Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | Master Protocol Personalising Treatment For Pancreatic Cancer |
| Trial | PRIMUS-001 |
|---|---|
| Cancer Type | Gastrointestinal and Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation |
| Trial | SCOPE 2 |
|---|---|
| Cancer Type | Gastrointestinal and Oesophageal Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) |
